MX2014010849A - Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico. - Google Patents

Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.

Info

Publication number
MX2014010849A
MX2014010849A MX2014010849A MX2014010849A MX2014010849A MX 2014010849 A MX2014010849 A MX 2014010849A MX 2014010849 A MX2014010849 A MX 2014010849A MX 2014010849 A MX2014010849 A MX 2014010849A MX 2014010849 A MX2014010849 A MX 2014010849A
Authority
MX
Mexico
Prior art keywords
growth factor
kinase inhibitor
factor receptor
epidermal growth
solid forms
Prior art date
Application number
MX2014010849A
Other languages
English (en)
Other versions
MX356753B (es
Inventor
Mei Lai
Original Assignee
Celgene Avilomics Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Avilomics Res Inc filed Critical Celgene Avilomics Res Inc
Publication of MX2014010849A publication Critical patent/MX2014010849A/es
Publication of MX356753B publication Critical patent/MX356753B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención proporciona una forma sólida y composiciones de la misma, que son como un inhibidor de cinasas de EGFR y que exhibe características deseables para la misma.
MX2014010849A 2012-03-15 2013-03-13 Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico. MX356753B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611376P 2012-03-15 2012-03-15
PCT/US2013/030982 WO2013138495A1 (en) 2012-03-15 2013-03-13 Solid forms of an epidermal growth factor receptor kinase inhibitor

Publications (2)

Publication Number Publication Date
MX2014010849A true MX2014010849A (es) 2014-12-10
MX356753B MX356753B (es) 2018-06-12

Family

ID=49161778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010849A MX356753B (es) 2012-03-15 2013-03-13 Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.

Country Status (18)

Country Link
US (5) US9056839B2 (es)
EP (1) EP2825041B1 (es)
JP (2) JP6317319B2 (es)
KR (1) KR102081042B1 (es)
CN (2) CN108658873B (es)
AU (2) AU2016203338A1 (es)
BR (1) BR112014022789B1 (es)
CA (1) CA2866852C (es)
ES (1) ES2880109T3 (es)
HK (1) HK1205431A1 (es)
IL (1) IL234425B (es)
IN (1) IN2014DN07401A (es)
MX (1) MX356753B (es)
MY (1) MY169233A (es)
RU (1) RU2673077C2 (es)
SG (2) SG10201700804XA (es)
WO (1) WO2013138495A1 (es)
ZA (1) ZA201407441B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2635284B1 (en) 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
KR102081042B1 (ko) 2012-03-15 2020-02-26 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 고체 형태
CA2866857C (en) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
TW201446745A (zh) 2013-02-08 2014-12-16 Celgene Avilomics Res Inc Ｅｒｋ抑制劑及其用途
JP2016518408A (ja) * 2013-05-06 2016-06-23 クロヴィス・オンコロジー，インコーポレーテッド 上皮増殖因子受容体キナーゼ阻害剤の塩
WO2015050862A1 (en) 2013-10-02 2015-04-09 3M Innovative Properties Company Article comprising polyacrylate pressure sensitive primer and adhesive comprising polyacrylate component
US10113089B2 (en) 2013-10-02 2018-10-30 3M Innovative Properties Company Articles and methods comprising polyacrylate primer with nitrogen-containing polymer
NO2718543T3 (es) 2014-02-04 2018-01-06
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
WO2016029002A2 (en) * 2014-08-22 2016-02-25 Clovis Oncology, Inc. Growth factor receptor inhibitors
BR112017012136A2 (pt) 2014-12-12 2018-01-02 Merck Patent Gmbh Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr
CN104961688A (zh) * 2014-12-25 2015-10-07 苏州晶云药物科技有限公司 一种表皮生长因子受体激酶抑制剂的磷酸盐及其制备方法
WO2016101912A1 (zh) * 2014-12-25 2016-06-30 苏州晶云药物科技有限公司 一种表皮生长因子受体激酶抑制剂的盐的晶型及其制备方法
JP6457697B2 (ja) 2015-04-29 2019-01-23 カントン チョンション ファーマシューティカル カンパニー，リミティド キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
CN106146406A (zh) * 2016-02-23 2016-11-23 深圳市塔吉瑞生物医药有限公司 一种取代的二氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN107663207B (zh) * 2016-07-27 2021-07-30 南京圣和药业股份有限公司 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法
CN107663208B (zh) * 2016-07-27 2021-10-15 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的药用盐及其制备方法与用途
CN107955019B (zh) * 2016-10-17 2021-09-14 广东众生药业股份有限公司 一种egfr抑制剂的盐型、晶型及其制备方法
CN108299419B (zh) * 2017-01-11 2022-04-26 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
JPH0741461A (ja) 1993-05-27 1995-02-10 Eisai Co Ltd スルホン酸エステル誘導体
DK0813525T3 (da) 1995-03-10 2004-02-16 Berlex Lab Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
UA70966C2 (uk) 1998-11-10 2004-11-15 Янссен Фармацевтика Н.В. Піримідини, що інгібують реплікацію віл
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
US6127376A (en) 1998-12-04 2000-10-03 Berlex Laboratories, Inc. Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
EP1150955A2 (en) 1999-02-04 2001-11-07 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE60004671T2 (de) 1999-06-29 2004-07-29 EGIS Gyógyszergyár Rt. Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
DE60043397D1 (de) 1999-12-28 2010-01-07 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
JP4969010B2 (ja) 2000-05-08 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害性ピリミジンのプロドラッグ
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US7427689B2 (en) 2000-07-28 2008-09-23 Georgetown University ErbB-2 selective small molecule kinase inhibitors
JP3748536B2 (ja) * 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
US6908906B2 (en) * 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
KR20040048920A (ko) 2001-11-01 2004-06-10 얀센 파마슈티카 엔.브이. 글리코겐 신타아제 키나제 3-베타 저해제(ｇｓｋ저해제)로서의 헤테로아릴 아민
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA04007637A (es) 2002-02-08 2004-11-10 Smithkline Beecham Corp Compuestos de pirimidina.
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US7202033B2 (en) 2002-03-21 2007-04-10 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
US20040002395A1 (en) 2002-06-27 2004-01-01 Poynor Raymond L. Bridge weight for metal wood golf club
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
CA2439440A1 (en) 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
AU2002951853A0 (en) 2002-10-04 2002-10-24 Commonwealth Scientific And Industrial Research Organisation Crystal structure of erbb2 and uses thereof
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20070021449A1 (en) 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
ES2365223T3 (es) 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
CA2533320A1 (en) 2003-08-15 2006-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
JP2007505858A (ja) 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
WO2005063722A1 (en) 2003-12-19 2005-07-14 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
EP1704145B1 (en) 2004-01-12 2012-06-13 YM BioSciences Australia Pty Ltd Selective kinase inhibitors
CA2553729A1 (en) 2004-01-16 2005-08-04 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
EP1735268B1 (en) 2004-03-15 2012-02-15 Eli Lilly And Company Opioid receptor antagonists
WO2005105988A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Crystal structure of human jak3 kinase domain complex and binding pockets thereof
EP1763514A2 (en) 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
EP1766068A4 (en) 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419161D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
AU2005286592A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
BRPI0515935B8 (pt) 2004-09-30 2021-05-25 Janssen Sciences Ireland Uc pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica
JP2008515986A (ja) 2004-10-13 2008-05-15 ワイス Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
EP1805208A2 (en) 2004-10-20 2007-07-11 Proteolix, Inc. Labeled compounds for proteasome inhibition
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
EP1856053A1 (en) 2005-01-14 2007-11-21 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP2505591A1 (en) 2005-02-11 2012-10-03 Memorial Sloan-Kettering Cancer Center Methods and compositions for detecting a drug resistant EGFR mutant
WO2006101977A2 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
CA2604551A1 (en) 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
KR101312225B1 (ko) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1948617B1 (en) 2005-10-21 2011-07-27 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
CA2628283C (en) 2005-11-01 2017-06-27 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
EP1943233A2 (en) 2005-11-03 2008-07-16 Irm, Llc Compounds and compositions for protein kinase inhbitors
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
US20080318989A1 (en) 2005-12-19 2008-12-25 Burdick Daniel J Pyrimidine Kinase Inhibitors
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
WO2007089768A2 (en) 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
KR101411695B1 (ko) 2006-02-17 2014-07-03 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
EP1991532B1 (en) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
DK2004632T3 (da) 2006-03-30 2014-06-16 Janssen R & D Ireland Hiv-inhiberende 5-amidosubstituerede pyrimidiner
DE602007009508D1 (de) 2006-03-30 2010-11-11 Little Island Co Cork Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
KR20090031787A (ko) 2006-07-21 2009-03-27 노파르티스 아게 Ｊａｋ 키나제 억제제로서의 ２,４-디(아릴아미노)-피리미딘-５-카르복스아미드 화합물
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
SI2526771T1 (sl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
CA2673125C (en) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
DK2078026T3 (da) 2006-11-21 2012-04-30 Rigel Pharmaceuticals Inc Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf
CN103641833A (zh) 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101563327A (zh) 2006-12-19 2009-10-21 健泰科生物技术公司 嘧啶类激酶抑制剂
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
AU2007341227C1 (en) 2006-12-29 2013-08-29 Janssen Sciences Ireland Uc HIV inhibiting 6-substituted pyrimidines
ES2523863T3 (es) 2006-12-29 2014-12-02 Janssen R&D Ireland Pirimidinas 5,6-sustituidas inhibidoras del VIH
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
PT2114900T (pt) 2007-01-31 2019-01-17 Ym Biosciences Australia Pty Compostos à base de tiopirimidina e as suas utilizações
JP4221470B2 (ja) 2007-02-01 2009-02-12 トヨタ自動車株式会社 電動車両制御装置及び電動車両制御方法
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
CA2681248A1 (en) 2007-03-20 2008-09-25 Smithkline Beecham Corporation Chemical compounds
KR20090121399A (ko) 2007-03-20 2009-11-25 스미스클라인 비참 코포레이션 화합물
WO2008118822A1 (en) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2152079A4 (en) 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP2183225A1 (en) 2007-07-17 2010-05-12 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
WO2009029682A1 (en) 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
WO2009032694A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
MX2010002336A (es) 2007-08-28 2010-03-25 Irm Llc Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2214486A4 (en) 2007-10-19 2011-03-09 Avila Therapeutics Inc HETEROARYL COMPOUNDS AND ITS USES
EP2234986A2 (en) 2007-12-20 2010-10-06 Cellzome Limited Sulfamides as zap-70 inhibitors
EP2252300B1 (en) 2008-02-22 2016-10-19 Rigel Pharmaceuticals, Inc. Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
US8205348B2 (en) 2008-03-19 2012-06-26 Zashiki-Warashi Manufacturing Inc. Tile spacer and holder therefor
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
KR101956261B1 (ko) 2008-05-21 2019-03-08 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
KR101892989B1 (ko) * 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
JP2012501980A (ja) 2008-09-03 2012-01-26 バイエル・クロップサイエンス・アーゲー アルコキシ置換およびアルキルチオ置換アニリノピリミジン
WO2010077740A2 (en) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
CN102282174B (zh) 2009-01-15 2014-02-26 弗·哈夫曼-拉罗切有限公司 抗人epo受体的抗体
WO2010112210A1 (en) 2009-04-03 2010-10-07 Cellzome Ag Methods for the identification of kinase interacting molecules and for the purification of kinase proteins
US9908884B2 (en) * 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
ES2559230T3 (es) 2009-05-08 2016-02-11 Astellas Pharma Inc. Compuesto de diamino-carboxamida heterocíclica
WO2010146132A1 (en) 2009-06-18 2010-12-23 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
CA3154024C (en) 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JP6068340B2 (ja) 2010-08-10 2017-01-25 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｂｔｋ阻害剤のベシル酸塩
US20130317029A1 (en) 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
EP2635284B1 (en) 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
CN102558149A (zh) 2010-12-29 2012-07-11 中国医学科学院药物研究所 嘧啶衍生物、及其制法和药物组合物与用途
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2012158843A2 (en) 2011-05-17 2012-11-22 The Regents Of The University Of California Kinase inhibitors
CN103159742B (zh) 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
KR102081042B1 (ko) 2012-03-15 2020-02-26 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 고체 형태
CA2866857C (en) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
EA201590822A1 (ru) 2012-11-02 2016-01-29 Фармасайкликс, Инк. Адъювантная терапия ингибитором киназы семейства tec

Also Published As

Publication number Publication date
US20190151313A1 (en) 2019-05-23
CN108658873B (zh) 2021-09-14
IN2014DN07401A (es) 2015-04-24
CA2866852A1 (en) 2013-09-19
CN108658873A (zh) 2018-10-16
AU2018201897A1 (en) 2018-04-12
EP2825041B1 (en) 2021-04-21
CN104302178A (zh) 2015-01-21
SG11201405691WA (en) 2014-10-30
JP6317319B2 (ja) 2018-04-25
EP2825041A4 (en) 2015-08-26
JP2018024713A (ja) 2018-02-15
SG10201700804XA (en) 2017-03-30
CN104302178B (zh) 2018-07-13
IL234425B (en) 2019-03-31
HK1205431A1 (en) 2015-12-18
BR112014022789A2 (pt) 2021-05-25
CA2866852C (en) 2020-12-29
WO2013138495A1 (en) 2013-09-19
KR20140145157A (ko) 2014-12-22
RU2673077C2 (ru) 2018-11-22
RU2014136896A (ru) 2016-05-10
AU2018201897B2 (en) 2019-10-31
MX356753B (es) 2018-06-12
AU2016203338A1 (en) 2016-06-16
BR112014022789B1 (pt) 2022-04-19
ES2880109T3 (es) 2021-11-23
US10004741B2 (en) 2018-06-26
US9539255B2 (en) 2017-01-10
US9056839B2 (en) 2015-06-16
US20170281623A1 (en) 2017-10-05
AU2013201520A1 (en) 2013-10-03
US10946016B2 (en) 2021-03-16
ZA201407441B (en) 2022-05-25
US20130267530A1 (en) 2013-10-10
JP2015514060A (ja) 2015-05-18
US20220062280A1 (en) 2022-03-03
KR102081042B1 (ko) 2020-02-26
AU2013201520B2 (en) 2016-02-25
US20160022677A1 (en) 2016-01-28
MY169233A (en) 2019-03-19
EP2825041A1 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
MX356753B (es) Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
PH12014502037A1 (en) Salts of an epidermal growth factor receptor kinase inhibitor
NZ721217A (en) Biaryl inhibitors of bruton’s tyrosine kinase
PH12018501463A1 (en) Pyrimidinyl tyrosine kinase inhibitors
EP3656769A4 (en) ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR
MX336875B (es) Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
IL239218A0 (en) Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation
WO2013185082A3 (en) Inhibitors of bruton's tyrosine kinase
MX355728B (es) Inhibidores de cinasas.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
IN2014DN09346A (es)
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
IN2015DN00127A (es)
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
EP3083559A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EP3082807A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3727387A4 (en) PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
NZ737572A (en) Intermediate compounds for the preparation of bipiperidine-2-one compounds
NZ743260A (en) Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration